AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

benzinga.com/news/health-care/25/07/46444819/astrazenecas-therapy-for-rare-protein-deposit-condition-fails

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program.
The trial showed that anselamimab, a light chain depleter antibody, did not achieve statistical significance for the primary endpoint…

This story appeared on benzinga.com, 2025-07-16 14:45:36.
The Entire Business World on a Single Page. Free to Use →